Page 2 - Accelerate Access News Today

Newly Appointed Leader and Key Investments Further Expand Partnerships Program and Accelerate Access to Relationship Marketing SolutionsNASHVILLE, Tenn., Feb. 09, 2023last month and the company's focus

07.06.2022 - Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced the Annals of Internal Medicine has published additional data from the Phase 3 MOVe-OUT trial evaluating LAGEVRIO (molnupiravir), an ...

Merck Has Completed Manufacturing of 10 Million Courses of Therapy and Remains on Track to Produce at Least 20 Million Courses in 2022 to Provide Widespread Access to Molnupiravir GloballyKENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)--$MRK #MRK--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and R...

08.02.2022 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that a total of approximately 3.1 million courses of molnupiravir, an investigational oral antiviral COVID-19 medicine, have been ...

/PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) Chief Executive Officer, Francis deSouza, discussed today the companys strong growth trajectory, including 2021...

GuruFocus Article or News written by PRNewswire and the topic is about:

/PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) Chief Executive Officer, Francis deSouza, discussed today the companys strong growth trajectory, including 2021...

Molnupiravir was the first oral COVID-19 antiviral medicine to receive authorization on Nov. 4, when the U.K.’s Medicines and Healthcare Products Regulatory Agency granted authorization.

Press release content from Business Wire. The AP news staff was not involved in its creation.

24.12.2021 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that Japan’s Ministry of Health, Labor and Welfare has granted Special Approval for Emergency in Japan for molnupiravir, an ...